MoonLake Immunotherapeutics(US:MLTX) Prnewswire·2025-10-16 21:36Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly making false and misleading statements regarding its drug candidate, sonelokimab (SLK), leading to significant investor losses following disappointing clinical trial results [3][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company based in Zug, Switzerland [2]. Legal Action Details - The lawsuit is on behalf of investors who purchased MoonLake shares from March 10, 2024, to September 29, 2025, with a deadline for potential lead plaintiff appointment set for December 15, 2025 [1][2]. - The complaint claims that MoonLake and its executives misrepresented SLK's advantages over traditional monoclonal antibodies, specifically FDA-approved BIMZELX [3]. Clinical Trial Results - On September 28, 2025, MoonLake announced Phase 3 clinical trial results for SLK, which reportedly did not demonstrate efficacy comparable to BIMZELX, leading analysts to label the results as "disastrous" [4]. - Following the announcement, MoonLake's stock plummeted nearly 90%, equating to a loss of $55.75 per share in a single trading session [4].